Amgen, Inc.

Amgen presents new oncology data at ESMO Congress 2024, highlighting targeted therapies for colorectal, lung, prostate, and gastric cancers, reflecting their strategy to advance diverse modalities for difficult-to-treat cancers.

Various researchers report financial relationships with pharmaceutical companies, including Deciphera, during and outside the conduct of the study.

The Amgen Biotech Experience (ABE) reached one million secondary school students worldwide, celebrated in Ireland with taoiseach Simon Harris and Amgen CEO Bob Bradway. ABE, established in 1990, has expanded biotechnology education to 16 countries, providing hands-on experience and professional development for teachers. The program aims to inspire students to pursue scientific careers and address real-world challenges.

Personalized medicine market to reach $900.67 Bn by 2030, driven by cancer therapies and genetic tech. North America leads, emphasizing personalized nutrition and expanding therapeutic applications.

The 'Migraine: Seven-Market Drug Forecast and Market Analysis' report, added to ResearchAndMarkets.com's offering, forecasts the migraine market in the US, France, Germany, Italy, Spain, the UK, and Japan to grow from $9.2 billion in 2023 to $16.4 billion by 2033, driven by a 6.0% CAGR. The report covers epidemiology, treatment options, unmet needs, pipeline analysis, and market competition.

EQBMED announces Amgen and Merck as sponsors for local clinical trial sites, focusing on oncology and cardiovascular disease, aiming to enhance diversity in clinical trials.

Novo Nordisk and Eli Lilly face competition from 16 new obesity drugs expected to launch by 2029, driving a $70 billion GLP-1 market by 2031. Price declines may accelerate over 10% annually by 2027. Rivals include Roche, Amgen, Pfizer, AstraZeneca, Boehringer, Viking Therapeutics, and Structure Therapeutics. The report predicts better efficacy, convenience, and tolerability for upcoming drugs.

Sally Lau, MD, discusses her role in the DeLLphi-304 trial, focusing on the accelerated approval of Imdelltra for relapsed small-cell lung cancer. She highlights the importance of nurse navigators and diversity grants in supporting patient enrollment and retention in trials, emphasizing the need for early involvement and responsive sponsors. Lau's passion for clinical trials stems from witnessing direct patient benefits and innovative treatment approaches.